Impact of lapatinib monotherapy on QOL and pain symptoms in patients with HER2+ relapsed or refractory inflammatory breast cancer

References

• Liauw S, Benda R, Morris C, et al. Inflammatory breast carcinoma: outcomes with trimodality therapy for nonmetastatic disease. Cancer 2004;100:920-8
   PubMed Web of Science ®Google Scholar
• Giordano SH, Hortobagyi GN. Inflammatory breast cancer: clinical progress and the main problems that must be addressed. Breast Cancer Res 2003;5:284-8
   PubMed Web of Science ®Google Scholar
• Chang S, Parker SL, Pham T, et al. Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975-1992. Cancer 1998;82:2366-72
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Buzdar AU, Hortobagyi GN. Update on the management of inflammatory breast cancer. Oncologist 2003;8:141-8
   PubMed Web of Science ®Google Scholar
• Kleer CG, van Golen KL, Merajver SD. Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res 2000;2:423-9
   PubMed Web of Science ®Google Scholar
• Low JA, Berman AW, Steinberg SM, et al. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol 2004;22:4067-74
   PubMed Web of Science ®Google Scholar
• Coleman RE. Skeletal complications of malignancy. Cancer 1997;80:1588-94
   PubMed Web of Science ®Google Scholar
• Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol 2004;22:3608-17
   PubMed Web of Science ®Google Scholar
• Lin NU, Winer EP. Brain metastases: the HER2 paradigm. Clin Cancer Res 2007;13:1648-55
   PubMed Web of Science ®Google Scholar
• Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-93
   PubMed Web of Science ®Google Scholar
• Sherrill B, Amonkar MM, Stein S, et al. Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer. Br J Cancer 2008;99:711-15
   PubMed Web of Science ®Google Scholar
• Zhou X, Cella D, Cameron D, et al. Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. Breast Cancer Res Treat 2009;117:577-89
   PubMed Web of Science ®Google Scholar
• Burris III HA, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005;3:5305-13
   Web of Science ®Google Scholar
• Jones SF, Hainsworth JD, Spigel DR, et al. A phase I study of the dual kinase inhibitor GW572016 in combination with paclitaxel (EGF10009). J Clin Oncol 2004; 22(Suppl):147s, (abstr 2083)
   Google Scholar
• Kaufman B, Trudeau M, Awada A, et al. Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. Lancet Oncol 2009;10:581-8
   PubMed Web of Science ®Google Scholar
• Johnston S, Trudeau M, Kaufman B, et al. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol 2008;26:1066-72
   PubMed Web of Science ®Google Scholar
• Fayers P, Aaronson NK, Bjordal K, et al. EORTC QLQ-C30 scoring manual. Brussels: EORTC Publications, 1997
   Google Scholar
• Cleeland CS. Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994;23:129-38
   PubMedGoogle Scholar
• Cleeland CS, Nakamura Y, Mendoza TR, et al. Dimensions of the impact of cancer pain in a four country sample: new information from multidimensional scaling. Pain 1996;67:267-73
   PubMed Web of Science ®Google Scholar
• Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998;16:139-44
   PubMed Web of Science ®Google Scholar
• Norman GR, Wyrwich KW, Sloan JA. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003;41:582-92
   PubMed Web of Science ®Google Scholar
• Atherton PJ, Novotny PJ, Jasperson B, et al. So what happened to all the patients? Event charts for summarizing clinically significant changes in oncology quality of life data. Proc Am Soc Clin Oncol 2001;20:abstr 1590. Available at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=10&abstractID=1590. [Last accessed 22 May 2009]
   Google Scholar
• Hobday TJ, Kugler JW, Mahoney MR, et al. Efficacy and quality of life data are related in a phase II trial of oral chemotherapy in previously untreated patients with metastatic colorectal carcinoma. J Clin Oncol 2002;20:4574-80
   PubMed Web of Science ®Google Scholar
• Crown JP, Burris III HA, Boyle F, et al. Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. Breast Cancer Res Treat 2008;12:317-25
   Web of Science ®Google Scholar
• Montazeri A. Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007. J Exp Clin Cancer Res 2008;27:32
   PubMed Web of Science ®Google Scholar
• Seidman AD, Portenoy R, Yao TJ, et al. Quality of life in phase II trials – a study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel, plus granulocyte colony stimulating factor. J Natl Cancer Inst 1995;187:1316-22
   Google Scholar
• Shimozuma K, Sonoo H, Ichihara K, et al. The prognostic value of quality of life scores: preliminary results of an analysis of patients with breast cancer. Surg Today 2000;30:255-61
   PubMed Web of Science ®Google Scholar